

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: PETERS, Dan et al. Conf.:
Appl. No.: NEW Group:
Filed: May 25, 2001 Examiner:
For: 8-AZABICYCLO[3.2.1]OCT-2-ENE AND
-OCTANE DERIVATIVES

L E T T E R

Assistant Commissioner for Patents
Washington, DC 20231

May 25, 2001

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 C.F.R. § 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):


<u>Country</u>	<u>Application No.</u>	<u>Filed</u>
DENMARK	PA 1998 01570	November 27, 1998

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32,565
for Gerald M. Murphy, Jr., #28,977

GMM/las
2815-0154P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment



Kongeriget Danmark

Patent application No.: PA 1998 01570
Date of filing: 27 November 1998
Applicant: NeuroSearch A/S
Smedeland 26B
DK-2600 Glostrup

The attached photocopy is a true copy of the following document:

- The specification and claims as filed with the application on the filing date indicated above.



Patent- og
Varemærkestyrelsen
Erhvervsministeriet

TAASTRUP 14 February 2001

Lizzi Vester

Lizzi Vester
Head of Section

Peters, Dan et al.
May 25, 2001
DSKB
(703) 205-8000
2815-0154P
1 of 1



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 451/02, A61K 31/46, A61P 25/00		A1	(11) International Publication Number: WO 00/32600
			(43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/DK99/00661			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 26 November 1999 (26.11.99)			
(30) Priority Data: PA 1998 01570 27 November 1998 (27.11.98) DK			
(71) Applicant (for all designated States except US): NEUROSEARCH A/S [DK/DK]; Pederstrupvej 93, DK-2750 Ballerup (DK).			
(72) Inventors; and (75) Inventors/Applicants (for US only): PETERS, Dan [SE/SE]; Nygatan 17, S-232 31 Arlöv (SE). OLSEN, Gunnar, M. [DK/DK]; (DK). NIELSEN, Simon, Feldbæk [DK/DK]; NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup (DK). NIELSEN, Elsebet, Østergaard [DK/DK]; NeuroSearch A/S, Pederstrupvej 93, Dk-2750 Ballerup (DK).			
(74) Common Representative: NEUROSEARCH A/S; Patent Department, Pederstrupvej 93, DK-2750 Ballerup (DK).			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: 8-AZABICYCLO[3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES

(57) Abstract

The present invention relates to novel 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.